SMMT - Summit lead asset beats Merck's Keytruda in a first in lung cancer
2024-05-30 15:12:02 ET
More on Summit Therapeutics
- Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
- Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
- Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
- Summit Therapeutics falls after late-stage data for lead asset
- Summit spikes as Citi launches at Buy on lead asset